TNG:EPA
Transgene SA
€ ०.७०
arrow_downward
-१.९६%(-०.०१४) 1D
अक्टोबर २, १७:३५:०८ GMT+२ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for TNG...
Open
€ ०.७०
High
€ ०.७०
Low
€ ०.६९
Mkt. cap
१९.६६ करोड
Avg. vol.
१.४० लाख
Volume
१.६७ लाख
52-wk high
€ १.५०
52-wk low
€ ०.६९
EPS
-€ ०.१७
Shares outstanding
२७.८६ करोड
No. of employees
१६०
Open
€ ०.७०
High
€ ०.७०
Low
€ ०.६९
Mkt. cap
१९.६६ करोड
Avg. vol.
१.४० लाख
Volume
१.६७ लाख
52-wk high
€ १.५०
52-wk low
€ ०.६९
EPS
-€ ०.१७
Shares outstanding
२७.८६ करोड
No. of employees
१६०
News stories
From web sources and news partners
FXLeaders
·
१४ मिनेट पहिले
Ripple bullish forecast: Evernorth’s 473M XRP Token Nasdaq Debut Could Trigger a Supply Crunch
Business Insider
·
२१ मिनेट पहिले
The NYSE's Most Famous Floor Trader Says AI Can't Take His Job
Simply Wall Street
·
२३ मिनेट पहिले
Nasdaq (NDAQ) Stock May Be 3% Overvalued Following Calypso AI Launch
WSJ
·
१३ घण्टा पहिले
Nasdaq Leads Stocks Higher as Hiring Softens
Profile
Transgene S.A. is a French biotechnology company founded in 1979. It is based in Illkirch-Graffenstaden, near Strasbourg, Alsace. The company develops and manufactures immunotherapies for the treatment of cancer. Based on viral vectors, these therapies stimulate the immune defenses of patients to specifically target cancer cells.
Transgene has two technological platforms based on these respective approaches: individual therapeutic vaccines, shared antigens cancer vaccines oncolytic viruses.
Transgene's portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer.
The company is listed on the regulated market of Euronext in Paris. Wikipedia
About Transgene SA